. 2022 Jun 6;166(4):507–521. doi: 10.1111/imm.13515

TABLE 1.

EC₅₀ values and the 95% confidence intervals (CI) were determined for monalizumab and Z199 for their ability to block the HLA‐E^peptide/NKG2A interaction in a functional assay.

	Functional EC₅₀ values
Mab	Peptide‐HLA‐E complex	EC₅₀ (ng/ml)	95% CI
Monalizumab	HLA‐E^HLA‐G	2111	1560–2855
	HLA‐E^HLA‐B8	278	224.3–344.5
	HLA‐E^HLA‐A2	237.8	187–302.5
	HLA‐E^HLA‐C4	140.2	77.73–252.7
Z199	HLA‐E^HLA‐G	5698	3311–9804
	HLA‐E^HLA‐B8	244.5	162.6–367.6
	HLA‐E^HLA‐A2	123.7	77.31–197.9
	HLA‐E^HLA‐C4	25.11	17.77–35.49

Note: Data from three (monalizumab) and two (Z199) independent experiments performed in duplicate were used to calculate the EC₅₀ values.